Ophthalmogenetics and Gene Therapy

Ophthalmic hereditary qualities are worried about the hereditary commitment to ophthalmic illness, including assurance of examples and dangers of legacy, and in addition finding, visualization, and advancement of medications for hereditary variations from the norm. The advances in gene therapy maintain extensive promise for the cure of ophthalmic conditions. Gene therapy is additionally in a position to deal with primary open-angle glaucoma (POAG) in animal models, and research show it is economically viable. Genes may additionally be delivered into cells in vitro or in vivo making use of viral or non-viral vectors. Recent technical advances have led to the demonstration of the molecular basis of a range of ocular diseases.

  • Genetics of Myopia Development
  • Gene Therapy
  • Usher syndrome
  • Familial exudative vitreal retinopathy
  • Retinoblastoma
  • Leber hereditary optic neuropathy (LHON)
  • Optic atrophy
  • Genetics of Myopia Development

Related Conference of Ophthalmogenetics and Gene Therapy

October 15-16, 2026

8th International Conference on Optometry

Paris, France
December 03-04, 2026

9th International Eye and Vision Congress

Madrid, Spain
March 25-26, 2027

41st European Ophthalmology Congress

Paris, France
April 28-29, 2027

4th International Conference on Ophthalmology

Paris, France

Ophthalmogenetics and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in